This is definitely a season of deals in the health care space, with Forest Labs (NYSE: FRX ) choosing to add another asset to its GI business ahead of its anticipated merger with Actavis (NYSE: ACT ) . Forest Labs is offering a significant premium for Furiex Pharmaceuticals (NASDAQ: FURX )
and there are still FDA-related risks in play, but it seems like a
reasonable offer for what could prove to be a highly synergistic asset.
Read the full article here:
For Forest Labs, Inc, Deals Are Coming Fast And Furiex
No comments:
Post a Comment